Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- cardiac
- Drug Discovery
- Genome
- Biotechnology
- Disease
- Therapeutic
- Stem cells
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 306186
License Grant
Licensor grants the Licensee of China a right and license under the Licensor IP to
(a) develop, use, demonstrate, sell, offer for sale, market, distribute, and promote Products in the Territory for use in the Field, exclusively,
(b) import Products into the Territory for use in the Field; exclusively;
(c) test and conduct independent Phase 3 clinical studies/trials on or Products in in the Territory, exclusively, and,
(d) manufacture, have manufactured, the Products solely in mainland China solely for use in the Territory and in the Field, non-exclusively.
License Property
Licensor is developing a gene therapy treatment, known as Generx.
Compound means Ad5FGF-4, alferminogene tadenovec, an angiogenic gene therapeutic, and natural evolutions thereof.
Product shall mean any biopharmaceutical product containing the Compound, alone or in combination with one or more other active pharmaceutical ingredients, in any dosage form or formulation, including any lyophilized forms thereof.
Field of Use
Field shall mean a treatment for patients with refractory angina, with myocardial ischemia, and other adverse medical conditions resulting from cardiac microvascular insufficiency.
The initial medical indication will be for the treatment of patients with refractory angina due to ischemic heart disease.
Ischemic heart disease is a condition of recurring chest pain or discomfort that occurs when a part of the heart does not receive enough blood. This condition occurs most often during exertion or excitement, when the heart requires greater blood flow.
IPSCIO Record ID: 90513
License Grant
Licensor grants to the Hong Kong Licensee and its Affiliates a royalty-bearing, sublicensable exclusive license to develop the Compounds or Products, including the development of derivative products; use, demonstrate or test the Compounds or Products in the Territory, including use in clinical trials and related procedures necessary to secure Marketing Approval in the Territory; manufacture, make, and have made, the Compounds and/or Products, solely for use in the Territory and in the Field; import the Compounds and/or Products into the Territory; and offer for sale, sell, market, distribute and promote Compounds and/or Products, solely in the Territory for use in the Field.
License Property
'Compound' refers to Ad5FGF-4, alferminogene tadenovec, an angiogenic gene therapeutic.
'Product' refers to any biopharmaceutical product containing the Compound, alone or in combination with one or more other active pharmaceutical ingredients, in any dosage form or formulation, including any lyophilized forms thereof. The product is an angiogenic gene therapy treatment, known as Generx.
Field of Use
The field of use is a treatment for patients with refractory angina, with myocardial ischemia, and other adverse medical conditions resulting from cardiac microvascular insufficiency.
Refractory angina (RA) is conventionally defined as a chronic condition characterised by angina in the setting of coronary artery disease (CAD),
IPSCIO Record ID: 28042
License Grant
As part of Licensee's acquisition of the Licensor's portfolio of cardiovascular growth factor therapeutic assets, pursuant to a Technology Transfer Agreement entered into between the Licensor and the Licensee, Licensee acquired a portfolio of methods and compositions directed at the treatment of cardiovascular diseases. Licensee also has exclusive licenses to methods for introducing DNA to the heart and for improving heart muscle function, as well as to various biologics. The Licensee's resulting portfolio of cardiovascular product candidates and associated intellectual property include methods and genes applicable to the treatment of heart diseases, the promotion of healing, and the treatment of peripheral vascular disease. Among the product candidates we acquired are Generx and Corgentin. Generx (alferminogene tadenovex) is a DNA-based, myocardial-derived growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. Angina, which is often felt as severe chest pain, can significantly limit patients’ mobility and quality of life and is a disorder that affects millions of adults in the United States and elsewhere. In addition, we have secured the rights to Genvascor, a pre-clinical, DNA-based, endothelial nitric oxide synthase (eNOS) therapeutic.
License Property
Genvascor is being designed to induce production of nitric oxide and is directed at mediating the effects of multiple growth factors to enhance neovascularization and increased blood flow for the potential treatment of patients with critical limb ischemia due to advanced peripheral arterial occlusive disease (PAOD).
Field of Use
Licensee may elect to develop Genvascor alone or in collaboration with a development partner.
IPSCIO Record ID: 3533
License Grant
The Licensor and the Licensee entered into an Assignment and License Agreement, pursuant to which the Licensor granted the Licensee an exclusive, worldwide license and the assignment of patents relating to certain gene therapy applications of mSCF for the treatment of cardiac ischemia. The Licensee has the right to grant sublicenses to third parties under the agreement.
License Property
Licensor owns certain intellectual property (including an issued United States patent) relating to certain gene therapy methods for delivering stem cell factor coding sequences, in order to treat certain ischemic diseases.
The patents relate to certain gene therapy applications of the membrane-bound form of the Stem Cell Factor gene (mSCF) for treatment of cardiac ischemia.
The Licensor intellectual property and research involves gene therapy technologies.
Field of Use
The Licensee will use the rights to gene therapy applications for the membrane bound form of Stem Cell Factor, or mSCF, for treatment of cardiac ischemia. Cardiac ischemia occurs when blood flow to your heart muscle is decreased by a partial or complete blockage of your heart's arteries. The decrease in blood flow reduces your heart's oxygen supply and can damage your heart muscle, reducing its ability to pump efficiently.
IPSCIO Record ID: 328338
License Grant
Licensor grants the Licensee of Japan the right and license, with no right to sublicense except as provided under the Licensor Patents and the Know-How, solely to use the Licensed Compounds to conduct Development and to import, use, and sell Products solely for use in the Field within the Territory.
For Other Indications for Licensed Compounds, Licensor grants a right of first refusal to obtain licenses to use Licensed Compounds for other applications or indications outside the Field.
For Rights to Related Compounds. Licensor grants the right to include within the license rights granted under the License specific Related Compounds.
The Parties are to develop and commercialize LR-3280 and certain related oligonucleotide compounds in Japan and certain other countries in Asia for the prevention or treatment of restenosis in any blood vessel following an angioplasty or similar procedure, and Licensor will supply Licensee quantities of product containing such compounds for clinical use and commercial sale.
License Property
Licensor is engaged in research and development of, among other things, oligonucleotides and oligonucleotide analogs that may be useful for therapeutic treatment of disease conditions. Licensor is presently developing one such oligonucleotide compound, identified as LR-3280 targeted to c-myc mRNA, as a pharmaceutical product for the prevention or treatment of restenosis in any blood vessel following an angioplasty or similar procedure.
The patents subject matter includes but is not limited to
– Method of inhibition smooth muscle cell proliferation by treating with c-myc antisense;
– Method of treating restenosis by administrating c-myr antisense;
– Method of Inhibiting collagen synthesis by treating with c-myr antisense;
– Method of treating vascular grafts to reduce stenosis by applying c-myr antisense to graft; and,
– Pharmaceutical compositions for the above methods.
Licensed Compounds means the oligonucleotide compound identified by Licensor as LR-3280, and any other phosphorothioated oligonucleotidc compounds that now or hereafter are owned or Controlled by Licensor or its Affiliates and that specifically target the mRNA transcribed from the c-myc gene, or contain four deoxyguanosine nucleotides in a row and are developed by Licensor for use in the Field.
Clinical Trial Product means a product, appropriate for use in clinical trials, containing a Licensed Compound or placebo, as applicable, in the formulation as determined by Licensee.
Field of Use
Field means the prevention or treatment of restenosis in humans in any blood vessel by use of a Licensed Compound delivered to the affected blood vessel via a Delivery Means following any stenosis-reducing medical procedure that is Transient in nature and that is intended to reduce the obstruction of the blood flow in a stenosed vessel (including without limitation percutaneous transluminal angioplasty, percutaneous transluminal coronary angioplasty and angioplasty involving placement of an intravascular stent).
Restenosis is the recurrence of stenosis, a narrowing of a blood vessel, leading to restricted blood flow. Restenosis usually pertains to an artery or other large blood vessel that has become narrowed, received treatment to clear the blockage and subsequently become renarrowed.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
